The voltage-gated sodium channel NaV1.7 plays a critical role in pain pathways. 19
Introduction

34
Pain is a major clinical problem. A 2012 National Health Interview Survey 35 (NHIS) in the United States revealed that 25.3 million adults (11.2%) suffered from 36 daily (chronic) pain and 23.4 million (10.3%) reported severe pain within a previous 37 three-month period (Nahin, 2015) . Many types of chronic pain are difficult to treat as 38 most available drugs have limited efficacy and can cause side effects. There is thus a 39 huge unmet need for novel analgesics (Woodcock, 2009 ). Recent human and animal 40 genetic studies have indicated that the voltage-gated sodium channel (VGSC) NaV1.7 41 plays a crucial role in pain signaling (Dib-Hajj et al., 2013 , Cox et al., 2006 , Nassar et 42 al., 2004 , highlighting NaV1.7 as a promising drug target for development of novel 43 analgesics (Emery et al., 2016 . 44
VGSCs consist of a large pore-forming α-subunit (~260 kDa) together with 45 associated auxiliary β-subunits (33-36 kDa) and play a fundamental role in the 46 initiation and propagation of action potentials in electrically excitable cells. Nine 47 isoforms of α-subunits (NaV1.1-1.9) that display distinct expression patterns and 48 variable channel properties have been identified in mammals (Frank and Catterall, 49 2003) . NaV1.7, encoded by the gene SCN9A in humans, is selectively expressed 50 peripherally in dorsal root ganglion (DRG), trigeminal ganglia and sympathetic 51 neurons (Black et al., 2012 , Toledo-Aral et al., 1997 , as well as the central nervous 52 system (Branco et al., 2016 , Weiss et al., 2011 . As a large membrane ion channel, 53 NaV1.7 produces a fast-activating, fast-inactivating and slowly re-priming current 54 (Klugbauer et al., 1995) , acting as a threshold channel to contribute to the generation 55 and propagation of action potentials by amplifying small sub-threshold depolarisations 56 (Rush et al., 2007) . The particular electrophysiological characteristics of NaV1.7 57 suggests that it plays a key role in initiating action potentials in response to 58 depolarization of sensory neurons by noxious stimuli . In animal 59 studies, our previous results demonstrated that conditional NaV1.7 knockout mice 60 have major deficits in acute, inflammatory and neuropathic pain (Minett et al., 2012 , 61 Nassar et al., 2004 . Human genetic studies showed that loss of function mutations in 62 NaV1.7 lead to congenital insensitivity to pain whereas gain of function mutations 63 cause a range of painful inherited disorders (Dib-Hajj et al., 2013, Cox et al., 2006) . 64
Patients with recessive NaV1.7 mutations are normal (apart from being pain-free and 65 anosmic), suggesting selective NaV1.7 blocking drugs are therefore likely to be 66 effective analgesics with limited side effects (Cox et al., 2006) . Recent studies also 67 showed that NaV1.7 is involved in neurotransmitter release in both the olfactory bulb 68 and spinal cord (Minett et al., 2012 , Weiss et al., 2011 . 69
Over the past decade, an enormous effort has been made to develop selective 70 NaV1.7 blockers. Efficient selective NaV1.7 antagonists have been developed, 71 however, NaV1.7 antagonists require co-administration of opioids to be fully analgesic 72 (Minett et al., 2015) . NaV1.7 thus remains an important analgesic drug target and an 73 alternative strategy to target NaV1.7 could be to interfere with either intracellular 74 trafficking of the channel to the plasma membrane, or the downstream effects of the 75 channel on opioid peptide expression. Although some molecules, such as Crmp2, 76 ubiquitin ligase Nedd4-2, fibroblast growth factor 13 (FGF13) and PDZ domain-77 containing protein Pdzd2, have been associated with the regulation of trafficking and 78 degradation of NaV1.7, the entire protein-protein interaction network of NaV1.7 still 79 needs to be defined (Dustrude et al., 2013 , Laedermann et al., 2013 , Shao et al., 2009 Bao, 2015, Yang et al., 2017) .Affinity purification (AP) and targeted tandem affinity 81 purification (TAP) combined with mass spectrometry (MS) is a useful method for 82 mapping the organization of multiprotein complexes (Wildburger et al., 2015 , Angrand 83 et al., 2006 . Using the AP-MS or TAP-MS method to characterize protein complexes 84 from transgenic mice allows the identification of complexes in their native physiological 85 environment in contact with proteins that might only be specifically expressed in 86 certain tissues (Fernandez et al., 2009 ). The principal aim of this study was to identify 87 new protein interaction partners and networks involved in the trafficking and regulation 88 of sodium channel NaV1.7 using mass spectrometry and our recently generated 89 epitope (TAP)-tagged NaV1.7 knock-in mouse. Such information should throw new 90 light on the mechanisms through which NaV1.7 regulates a variety of physiological 91 systems, as well as propagating action potentials, especially in pain signaling 92 pathways. 93
Results
94
The TAP tag does not affect NaV1.7 channel function 95
Prior to generating the TAP-tagged NaV1.7 knock-in mouse, we tested the 96 channel function of TAP-tagged NaV1.7 in HEK293 cells by establishing a HEK293 97 cell line stably expressing TAP-tagged NaV1.7. A 5-kDa TAP tag consisting of a poly-98 histidine affinity tag (HAT) and a 3x FLAG tag in tandem (Terpe, 2003) , separated by 99 a unique TEV-protease cleavage site, was fused to the C-terminus of NaV1.7 ( Fig 1A) . 100
The expression of TAP-tagged NaV1.7 was detected with immunocytochemistry using 101 an anti-FLAG antibody. The result showed that all the HEK293 cells expressed TAP-102 tagged NaV1.7 ( Fig 1B) . The channel function of TAP-tagged NaV1.7 was examined 103 with electrophysiological analysis and the result showed that all the cells presented 104 normal functional NaV1.7 currents ( Fig 1C) . Activation and fast inactivation data were 105 identical for wild-type NaV1.7 and TAP-tagged NaV1.7 ( Fig 1D) demonstrating that the 106 TAP tag does not affect channel function of NaV1.7. 107
Generation of a TAP-tagged NaV1.7 mouse 108
We used a conventional gene targeting approach to generate an epitope-109 tagged NaV1.7 mouse. The gene targeting vector was constructed using an 110
Escherichia coli recombineering based method (Bence et al., 2005) S1 ). A TAP tag, which contains a HAT domain, a TEV cleavage site and 3x Flag tags 112 ( Fig 1A) , was inserted into the open reading frame at the 3'-end prior to the stop codon 113 in exon 27 of NaV1.7 (NCBI Reference: NM_001290675) ( Fig 2A) . The final targeting 114 vector construct containing a 5' homology arm (3.4 kb), a TAP tag, neomycin cassette 115 and a 3' homology arm (5.8 kb) ( Fig 2B) was transfected into the 129/Sv embryonic 116 stem (ES) cells. 12 colonies with the expected integration (targeting efficiency was 117 3.5%) were detected using Southern blot ( Fig 2C) . Germline transmission and intact 118 TAP tag insertion after removal of the neo cassette was confirmed with Southern blot, 119 PCR and RT-PCR, respectively ( Fig 2D-F) . This mouse line is henceforth referred to 120 as NaV1.7 TAP . 121
NaV1.7 TAP mice have normal pain behavior 122
The homozygous NaV1.7 TAP knock-in mice (KI) were healthy, fertile and 123 apparently normal. Motor function of the mice was examined with the Rotarod test. 124
The average time that KI animals stayed on the rod was similar to the WT mice ( Fig  125 the laterodorsal thalamic nucleus, and in the subfornical organ that is located in the 140 roof of the dorsal third ventricle (Fig 4E,F) and is involved in the control of thirst (Oka 141 et al., 2015) . The FLAG-tag was also present in neurons of the posterodorsal aspect 142 of the medial amygdala and in the hypothalamus in neurons of the arcuate nucleus 143 ( Fig 4G-I) as confirmed in a recent study (Branco et al., 2016) . A clear staining 144 appeared in neurons of the substantia nigra reticular region and the red nucleus 145 magnocellular region of the midbrain, and in neurons of the pontine nuclei located in 146 the hindbrain (Fig 4J-L) . In the spinal cord, FLAG-tag expression was visible in the 147 superficial layer of the dorsal horn. We co-stained the spinal cord with IB4, a marker 148 for the inner part of lamina II, and the results showed that the TAP-tagged NaV1.7 149 was expressed in Laminae I, II and III ( Fig 4M-O) . In the PNS, however, there was no 150 positive FLAG-tag staining found in DRG, sciatic nerve or skin nerve terminals (data 151 not shown). This could be because of masking of the tag in the PNS, preventing the 152 antibody binding. We also examined the TAP-tagged NaV1.7 expression pattern in 153 different tissues with Western blot using an anti-FLAG antibody. TAP-tagged NaV1.7 154 bands were present in olfactory bulb, hypothalamus, spinal cord, sciatic nerve and 155 DRG, but not in cortex, cerebellum, skin, lung, heart and pancreas ( Fig 5E) . 156
Optimisation of single-and tandem-affinity purification of TAP-tagged NaV1.7 157
The TAP tag on NaV1.7 offered a possibility of two consecutive affinity 158 purifications, a single-step affinity purification (ss-AP) ( Step 1 and 2) and tandem 159 affinity purification (Step 1 -4) ( Fig 5A) . CHAPS and DOC lysis buffers were evaluated 160 to solubilize TAP-tagged NaV1.7 and its protein complex from tissues, e.g. DRG, spinal 161 cord, olfactory bulbs and hypothalamus, in the Co-IP system. CHAPS is a non-162 denaturating zwitterionic detergent, commonly used to extract membrane proteins in 163 their native conformation. In comparison to strong anionic detergents like SDS, 164 CHAPS preserves protein-protein interactions and is compatible with downstream 165 applications such as mass spectrometry. The result showed that TAP-tagged NaV1.7 166 from DRG and olfactory bulbs was clearly solubilized and precipitated by both 167 purifications -ss-AP and tandem affinity purification in 1% CHAPS buffer ( Fig 5B) . 168 Also the result from ss-AP showed that TAP-tagged NaV1.7 could be 169 immunoprecipitated from hypothalamus, sciatic nerve, spinal cord, olfactory bulb and 170 DRG of KI mice, but not from these tissues of WT control mice ( Fig 5C) . However, the 171 DOC lysis buffer, which was used to investigate the TAP-tagged PSD-95 protein 172 complex (Fernandez et al., 2009 ), did not solubilize TAP-tagged NaV1.7 from mouse 173 tissue (data not shown). 174
Identification of TAP-tagged NaV1.7 associated complexes by AP-MS 175
We next identified the components of NaV1.7 complexes using ss-AP followed 176 by LC-MS/MS. Briefly, the TAP-tagged NaV1.7 complexes were extracted from DRG, 177 spinal cord, olfactory bulb and hypothalamus using ss-AP (see Materials and 178 Methods). In total 189,606 acquired spectra from 12 samples, in which each group (KI 179 and WT) contains 6 biological replicate samples and each sample was from one 180 mouse, were used for protein identification. 1,252 proteins were identified with a 181 calculated 0.96% false discovery rate (FDR). 267 proteins (Supplemental Tab S1) met 182 those criteria and were shortlisted based on the criteria described in Materials and 183
Methods. The proteins only appearing in NaV1.7 TAP mice and the representatively 184 selected proteins are listed in Table 1 . PANTHER cellular component analysis of these 185 267 proteins revealed 8 different cellular components ( Fig 6A) . These proteins were 186 further classified into 22 groups based on their function, including 12 membrane 187 trafficking proteins, 23 enzyme modulators and 4 transcription factors ( Fig 6B) . 188
Validation of TAP-tagged NaV1.7 interacting proteins using Co-IP 189
The physical interactions between NaV1.7 and interacting protein candidates 190 were assessed using Co-IP in an in vitro system by co-expressing the candidates in a 191 TAP-tagged NaV1.7 stable cell line. A number of candidates of interest, such as Syt2, 192 Gprin1, Lat1, and Tmed10, together with known NaV1.7 protein interactors Scn3b and 193 Crmp2 were chosen from the identified NaV1.7 associated protein list (Supplemental 194 Tab S1 and between these proteins and NaV1.7 by co-immunoprecipitation ( Fig 5D) . Next, we 198 investigated some potential novel binding partners, such as Syt2, Gprin1, Lat1, and 199
Tmed10. Synaptotagmin is a synaptic vesicle membrane protein that functions as a 200 calcium sensor for neurotransmission (Chapman, 2002) . Sampo et al. showed a direct 201 physical binding of synaptotagmin-1 with NaV1.2 at a site which is highly conserved 202 across all voltage-gated sodium channels (Sampo et al., 2000) suggesting that the 203 synaptotagmin family can associate with other VGSCs. NaV1.7 found at pre-synaptic 204 terminals appears to be involved in neurotransmitter release (Minett et al., 2012 , Black 205 et al., 2012 . Our Co-IP result shows that Syt2 was co-precipitated with TAP-tagged 206 NaV1.7 ( Fig 5D) . Interestingly other synaptic proteins also co-precipitated with Nav1.7 207 including SNARE complex protein Syntaxin-12 (Supplemental Tab S1). Gprin1 was 208 selected for further validation due to its involvement in regulating mu-opioid receptor 209 (MOR) activity (Ge et al., 2009) , highlighting a potential role in connection between 210 the opioid system and NaV1.7 in pain. Our Co-IP results confirmed the protein 211 interaction between Gprin1 and NaV1.7 ( Fig 5D) . Gabapentin was developed to treat 212 epilepsy, but it is now used to treat various forms of chronic pain. However, the 213 analgesic mechanisms of gabapentin are not entirely clear, but involve inhibiting the 214 function of N-type voltage-gated calcium channels (CaV2.2) by blocking the 215 association of pore-forming α1 subunits with auxiliary α2δ-1 subunits to reduce 216 channel activity, membrane trafficking, and neurotransmitter release in DRG neurons 217 (Kukkar et al., 2013) . As the transporter of gabapentin, Lat1 has been confirmed with 218
Co-IP ( Fig 5D) , suggesting that Lat1 and/or gabapentin may be involved in the 219 regulation of NaV1.7 channel function. However, future experiments are required to 220 determine the functional significance of the Nav1.7-Lat1 interaction in this regard. As 221 a member of the p24 family, Tmed10 was selected due to its well-characterised 222 properties as a protein trafficking regulator. Previous studies have highlighted that 223
Tmed10 plays an important role as a cargo receptor in the trafficking of various 224 membrane proteins. For example, Tmed10 has been observed to modulate the 225 transport and trafficking of amyloid-β precursor protein (Vetrivel et al., 2007) , 226 endogenous glycosylphosphatidylinositol (GPI)-anchored proteins CD59 and folate 227 receptor alpha (Bonnon et al., 2010) , and several G protein-coupled receptors 228 (GPCRs) (Luo et al., 2011) . Our Co-IP result showed that Tmed10 was co-229 immunoprecipitated with TAP-tagged NaV1.7 ( Fig 5D) , suggesting Tmed10 may 230 regulate NaV1.7 trafficking. In summary, all these four potential interacting proteins 231 selected for further validation were confirmed as interactors by Co-IP, giving 232 confidence in the Nav1.7 TAP mass spectrometry list. 233
Functional characterisation of Crmp2 234
Crmp2 is the presumed target of the anti-epileptic drug Lacosamide based on 235 binding studies (Wilson and Khanna, 2015) . We sought to evaluate the possible 236 electrophysiological effects of Crmp2 on NaV1.7 and in addition understand the 237 relevance of Crmp2 to the action of the drug on NaV1.7 current density. Transfection 238 of Crmp2 into a NaV1.7 stable HEK293 cell line revealed a nearly two-fold increase in 239 sodium current density ( Fig 7A-C ), suggesting Crmp2 acts as a transporter for NaV1.7 240 (Dustrude et al., 2013) . Next, we sought to investigate the effect of Lacosamide on 241 sodium currents. In cells not transfected with Crmp2, NaV1.7 currents displayed no 242 significant changes in current density following prolonged 5-hour exposure to 243 Lacosamide ( Fig 7A,B) . Interestingly, following 5-hour incubation with Lacosamide in 244 Crmp2 transfected cells, a complete reversal in the increase in NaV1.7 current density 245 provoked by Crmp2 was observed ( Fig 7A,D) . 246
Discussion
247
Experimental evidence has shown that protein-protein interactions play a key 248 role in trafficking, distribution, modulation and stability of ion channels (Catterall, 2010, 249 Bao, 2015, Chen-Izu et al., 2015 , Laedermann et al., 2015 , Shao et al., 2009 , Leterrier 250 et al., 2010 . Here, we mapped the protein-interaction network of NaV1.7 using an AP-251 MS proteomic approach with an epitope-tagged NaV1.7 knock-in mouse line. This is 252 the first report to define an ion channels' macromolecular complex using an epitope-253 tagged gene targeted mouse. 254 AP-MS requires specific high-affinity antibodies against the target proteins of 255 interest (Wildburger et al., 2015) . However, binding may compete with normal protein-256 protein interactions. To overcome these limitations, epitope tags on target proteins 257 were introduced into the AP-MS system. In the last decade, single-step and tandem 258 affinity purification have been widely applied in protein-protein interaction studies 259 (Wildburger et al., 2015 , Fernandez et al., 2009 . In contrast to ss-AP, TAP produces 260 lower background and less contamination. However, due to its longer experimental 261 washing procedures and two-step purification, TAP coupled with MS analysis may not 262 be a sensitive method to detect transient and dynamic protein-protein interactions. In 263 recent years, along with newly developed highly sensitive mass spectrometer 264 techniques and powerful quantitative proteomics analysis methods, ss-AP was 265 employed to identify both transient and stable protein-protein interactors (Keilhauer et 266 al., 2015 , Oeffinger, 2012 . For example, using a single-step FLAG approach, Chen 267 and colleagues defined specific novel interactors for the catalytic subunit of PP4, which 268 they had not previously observed with TAP-MS (Chen and Gingras, 2007). Thus, ss-269 AP followed by sensitive LC-MS/MS analysis was applied in this study. In fact, many 270 dynamic modulator proteins were identified to interact with NaV1.7 in this study, such 271 as Calmodulin (Calm1) (Supplemental Tab S1) which was found to bind to the C-272 terminus of other VGSCs NaV1.4 and NaV1.6, and regulates channel function (Herzog 273 et al., 2003) . Four proteins, Crmp2, Nedd4-2, FGF13 and Pdzd2, have previously been 274 NaV1.7 by a GST pull-down assay in an in vitro system (Shao et al., 2009 ). We did not 279 find the previously reported NaV1.7 interactors Nedd4-2, FGF13 and Pdzd2. This may 280 be because Nedd4-2 and FGF13 only binds to NaV1.7 in neuropathic pain and heat 281 nociception conditions, respectively, and Pdzd2 shows strong binding in vitro but not 282 in vivo. Apart from known NaV1.7 and other NaV protein interactors, we also identified 283 a broad range of important novel interactors that belong to different protein classes, 284 such as cytoskeletal/structural/cell adhesion proteins and 285 vesicular/trafficking/transport proteins ( Fig 6B) . 286
Using Co-IP and a co-expression in vitro system, we confirmed a direct physical 287 interaction between NaV1.7 and novel NaV1. Tab S1), the sodium channel β3 subunit and some CAMs such as Ncam1 and 301
Neurofascin, have been found to associate with the NaV1.7 α subunit. The crystal 302 structure of the human β3 subunit has been solved recently. The β3 subunit Ig-domain 303 assembles as a trimer in the crystal asymmetric unit (Namadurai et al., 2014) . This 304 raises the possibility that trimeric β3 subunits binding to NaV1.7 α subunit(s) form a 305 large complex together with other sodium channels, as well as CAMs and cytoskeletal 306 proteins in the plasma membrane. 307 NaV1.7 has also been linked to opioid peptide expression, and enhanced 308 activity of opioid receptors is found in the NaV1.7 null mutant mouse (Minett et al., 309 2015) . Interestingly, Gprin1, which is known to interact with opioid receptors as well 310 as other GPCRs, was found to co-immunoprecipitate with NaV1.7. This suggests that 311 GPCR sodium channel interactions could add another level of regulatory activity to the 312 expression of NaV1.7. More recently, Branco and colleagues reported that NaV1.7 in 313 hypothalamic neurons plays an important role in body weight control (Branco et al., 314 2016) . We found that NaV1.7 was not only present in the arcuate nucleus but also in 315 other regions of the brain such as the medial amygdala, medial habenula, anterodorsal 316 thalamic nucleus, laterodorsal thalamic nucleus, and in the subfornical organ, 317 substantia nigra reticular part and the red nucleus magnocellular part of the midbrain, 318 and in neurons of the pontine nuclei located in the hindbrain. NaV1.7 thus has other 319 functions in the CNS that remain to be elucidated. 320
Overall, the present findings provide new insights into the interactome of NaV1.7 321 for advancing our understanding of NaV1.7 function. Our data also show that the ss-322 AP coupled LC-MS/MS is a sensitive, reliable and high-throughput approach to identify 323 protein-protein interactors for membrane ion channels, using epitope-tagged gene 324 targeted mice. 325
Materials and Methods
326
Generation of a TAP-tagged NaV1.7 expressing stable HEK293 cell line 327 A HEK293 cell line stably expressing TAP tagged NaV1.7 was established as 328 previously described (Koenig et al., 2015) . Briefly, a sequence encoding a TAP tag 329 
Generation of NaV1.7 TAP knock-in mice 337
The gene targeting vector was generated using a BAC homologous recombineering-338 based method . Four steps were involved in this procedure ( To generate TAP tagged NaV1.7 mice, the linearized targeting vector was transfected 372 into 129/Sv ES cells. Cells resistant to G418 were selected by culturing for 9 days. 373
Recombined ES cell clones were identified using Southern blot-based screening. 374
Three Clones that were confirmed to be correct using Southern blot were injected into 375 C57BL/6 blastocysts at the Transgenic Mouse Core facility of the Institute of Child 376
Heath (ICH). The chimeric animals were crossed to C57BL/6 and the germline The wild-type NaV1.7 allele and TAP tagged NaV1.7 allele gave a 170bp band and a 385 411bp band, respectively. The TAP tagged NaV1.7 mRNA was confirmed by RT-PCR. 386
Briefly, the total RNA was extracted from dorsal root ganglia with Qiagen RNAEasy kit 387 (Qiagen) and 1.0 µg of total RNA was used to synthesize cDNA using Biorad cDNA 388 script-II synthesize kit with oligo-dT primer. The following primers were used to detect 389 mRNA of NaV1.7: 390
The wild-type and TAP tagged NaV1.7 alleles gave a 1521 bp band and a 1723 bp 393 band, respectively. 394
Immunocytochemistry 395 TAP tagged NaV1.7-HEK293 cells were plated on poly-D-lysine coated coverslips in 396 24-well plates and cultured at 37°C/5% CO2 in DMEM supplemented with 10% foetal 397 bovine serum (Life Technologies), 50 U/ml penicillin, 50 µg/ml streptomycin and 0.2 398 mg/ml G418. 24 hours later, the cells were fixed in cooled methanol at -20°C for 10 399 minutes, and then permeabilised with cooled acetone at -20°C for 1 minute. After 3 400 washes with 1x PBS, the cells were incubated with blocking buffer containing 1x PBS, 401 0.3% Triton X-100 and 10% goat serum at room temperature for 30 minutes. Then the 402 fixed cells were incubated with anti-FLAG antibody (1:500 in blocking buffer, F1804, Flag-tag immunohistochemistry, sections were incubated in blocking solution (4% 417 horse serum, 0.3% Triton X-100 in PBS) for 1 hour at room temperature, followed by 418 incubation in mouse anti-Flag antibody (F-1804, Sigma) diluted 1:200 in blocking 419 solution for 2 days at 4°C. Following three washes in PBS, bound antibody was 420 visualized using either an Alexa 488 or 594 conjugated goat anti mouse secondary 421 antibody (1:800, Invitrogen). The IB4 staining in spinal cord has been described in a 422 previous study (Zhao et al., 2010) . To facilitate the identification of brain regions and 423 the corresponding bregma levels, nuclei were counterstained with Hoechst 33342 424
(1:10,000, Invitrogen). Sections were mounted with a fluorescence mounting medium 425 
Western blot 466
Proteins were extracted from different tissues, such as DRG, spinal cord, olfactory 467 bulbs and brain in 1% CHAPS lysis buffer. Samples for western blot were prepared by 468 adding 3x Loading Buffer (Life Technologies) containing 5 mM DTT and denatured for 469 5 minutes at 95°C. 30μg of proteins were loaded in to precast gels (Bio-Rad) along 470 with a multicolour spectra high range protein ladder (Thermo Scientific). Gels were 471 placed in a gel tank and submerged in 1x Running Buffer. Samples were 472 electrophoresed for between 1-3 hours, depending on size of protein of interest at 120 473 volts. Immobilin-P membrane (Millipore) was activated with methanol (Sigma) followed 474 by wet transfer of proteins in 1x ice cold Transfer Buffer. Transfer was carried out for 475 1 hour at 100 volts. Membranes were then blocked using 5% Marvel dry milk in 1x 476 PBS. Antibody incubation was performed overnight at 4 o C. The membrane was then 477 washed and incubated with HRP tagged secondary antibody in PBS containing 2.5% 478 dry milk in 1x PBS, with agitation at room temperature. Membranes were then washed 479 and the proteins were visualised using Super Signal West Dura Extended Duration 480 Substrate (Thermo Scientific) on light sensitive film (GE Healthcare) and developed 481 on a Konica Minolta (SRX-101A) medical film developer. 482
Plasmids, cloning and primers 483
The following plasmids were obtained from Addgene (Cambridge, MA): Tmed10, 484 Gprin1 and Lat1. In order to perform in vitro validation of NaV1.7 interaction with 485
Synaptotagmin-2, we first cloned the human gene for insertion into a mammalian 486 expression plasmid. Synaptotagmin-2 was cloned from human dorsal root ganglion 487 neuronal tissue. Whole mRNA was first reverse transcribed into a cDNA library for 488 PCR. Following insertion into a TOPO vector, this was then used as the template to 489 create the Synaptotagmin-2 insert, which was then successfully cloned into a 490 pcDNA3.1 IRES-AcGFP plasmid using the Gibson assembly method. The Collapsin 491
Response Mediator Protein 2 (Crmp2) gene was cloned from human dorsal root 492 ganglia neuron mRNA and cloned into a pcDNA3.1 plasmid using Gibson assembly. 493
The Scn3b mammalian expressing vector was used to investigate loss-of-function of 494 NaV1.7 (Cox et al., 2006) . 495
Co-immunoprecipitation (Co-IP) 496
Mouse tissues used in immunoprecipitation experiments were chosen on the basis of 497 known NaV1.7 expression, these include the following: Olfactory bulb, hypothalamus, 498 spinal cord, dorsal root ganglia and sciatic nerve. All tissues from individual mice were 499 either pooled or treated as individual tissue samples depending on experimental 500 requirements. All tissues were flash frozen in dry ice immediately following dissection 501 and stored at -80°C to avoid protein degradation. HEK293 cells stably expressing 502 TAP-tagged NaV1.7 were harvested by trypsinisation followed by centrifugation at 800 503 rpm for 5 minutes. Cell pellets were stored at -80°C to avoid protein degradation. 504
Samples were lysed in a 1% CHAPS lysis buffer containing a protease inhibitor 505 cocktail and homogenised using ceramic zirconium oxide mix beads of 1.4 mm and 506 2.8 mm lysing kit and homogeniser (Precellys). A total of 10-25mg of protein was 507 incubated with M2 Magnetic FLAG coupled beads (Sigma-Aldrich) for 2h at 4°C. The 508 bead-protein complex was then washed with three cycles of 5 resin volumes of 1% 509 CHAPS buffer and once with TEV-protease buffer (Invitrogen). The tagged protein 510 was cleaved from the beads by the addition of TEV protease enzyme (Invitrogen) and 511 incubated for 3 hours at 37°C to elute the protein complex. Sample eluate was then 512 separated from the beads and stored at -80°C. 513
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis 514
Proteins cleaved from Ni-NTA beads after affinity purification were tryptic digested 515 Errors in series resistance were compensated by 70 to 75%. Cells were briefly washed 576 with extracellular solution before a final 2 mL of solution was transferred to the dish. 577
Cells were held at -100 mV for 2 minutes before experimental protocols were initiated. 578 Currents were elicited by 50 ms depolarisation steps from -80mV to + 80mV in 5mV 579 increments. Compounds were added and mixed at the desired concentrations in 580 extracellular solution before being added to the bath. Following addition of the 581 compound protocols were repeated on previously unrecorded cells. All currents were 582 leak substracted using a p/4 protocol. The following compounds were used in 583 electrophysiology experiments: Lacosamide ((R)-2-acetamido-N-benzyl-3-584 methoxypropionamide) was obtained from Toronto Research Chemicals Inc 585 (L098500) and Tetrodotoxin was obtained from Sigma-Aldrich (T8024). Incubation 586 with Lacosamide was done for 5 hours prior to recording. 587 Voltage-clamp experiments were analysed using cCLAMP software and Origin 588 (OriginLab Corp., Northampton, MA) software programs. Current density-voltage 589 (pA/pF) analysis by measuring peak currents at different applied voltage steps and 590 normalised to cell capacitance. Voltage dependent activation data was fitted to a 591
Boltzmann equation y = (A2 + (A1 − A2)/(1 + exp((Vh − x)/k))) * (x − Vrev), where A1 592 is the maximal amplitude, Vh is the potential of half-maximal activation, x is the 593 clamped membrane potential, Vrev is the reversal potential, and k is a constant. All 594 Boltzmann equations were fitted using ORIGIN software. 595
NaV1.7 interaction protein selection and function analysis 596
Candidate proteins that may interact with Nav1.7 were selected by two criteria: a) 597 Present in at least two knock-in biological experiments but absent from wild type 598 experiments. b) Present in more than three knock-in and more than one wild type 599 experiments, the ratio of average abundance is more than 1.5 fold increased in knock-600 in experiments as compared with wild type experiments. Further cellular component 601 and function classification were performed on PANTHER Classification System (11.0). 602 Ingenuity pathway analysis (IPA) (QIAGEN) was used to elucidate pathways and 603 protein interaction networks using candidate proteins. 604
Southern blot analysis 605
The genomic DNA was extracted from either ES cells or tails of mice following the 606 procedures as described (Sambrook and Russell, 2001) . The probes for Southern blot 607 were amplified by PCR using mouse genomic DNA isolated from C57BL/6 as a 608 template and purified with a Qiagen Gel Purification Kit. The restriction enzymes StuI, 609
BspHI and PsiI were used to digest genomic DNA for either wild-type and knock-in 610 bands. The sizes of wild-type and knock-in bands is shown in Fig 2B. The primers 611 used to create probes (5' external probe: 768 bp; 3' external probe: 629 bp) included: maximal activation (V1/2; -9.54 ± 1.08 mV for NaV1.7, n = 10; and -8.12 ± 1.07 mV for 849 TAP-tagged NaV1.7, n = 14; p = 0.3765, Student's t-test) and reversal potential (Vrev; 850 61.73 ± 3.35 mV for NaV1.7, n = 10; and -8.12 ± 1.07 mV for TAP-tagged NaV1.7, n = 851 14; p = 0.9114, Student's t-test). Right panel: Voltage dependence of fast inactivation, 852 assessed by submitting the cells to a 500 ms prepulse from -130 to -10 mV prior to 853 depolarization at -10 mV. No significant difference in the voltage of half inactivation was 854 observed between the two cell lines (V1/2 of -64.58 ± 1.32 mV for NaV1.7, n = 10; and -855 64.39 ± 1.06 for TAP-tagged NaV1.7, n = 14; p = 0.9100, Student's t-test). was then hybridized with either 5' or 3' external probe. Wild-type (WT) allele was 871 detected as a 13.8 kb fragment using either 5' or 3' probes. Knock-in allele (KI) 872 was detected as either a 6.6 kb (5' probe) or a 7.3 kb (3' probe) fragment. 873 D Southern blot analysis of TAP-tagged NaV1.7 allele after Cre recombination. 874
Genomic DNA was digested either with BspHI or PsiI, and was then hybridized 875 with either 5' (BspHI) or 3' (PsiI) external probe. WT alleles were detected as 5.8 876 kb (5' probe) and 8.4 kb (3' probe) fragments, respectively. The neo-deleted 877 TAP-tagged NaV1.7 alleles were detected as 4.5 kb (5' probe) and 6.1 kb (3' 878 probe) fragments, respectively. PCR was performed with the primers indicated with black arrows. A 1.5 kb WT 885 band and a 1.8 kb KI band were detected from either littermate WT control 886 animals or NaV1.7 TAP KI mice, respectively. 887
Figure 3. Pain behavior tests. 888
A Rotarod test showed no motor deficits in TAP-tagged NaV1.7 animals (n = 7, WT; n = 7, 889 KI; p = 0.8619, Student's t-test). The proteins from DRG and olfactory bulbs were extracted in 1% CHAPS lysis 940 buffer. After single-step and tandem affinity purification, TAP-tagged NaV1.7 941 were detected using Western blotting with anti-HAT antibody. 942
C
The proteins from different tissues including hypothalamus, sciatic nerve, spinal 943 cord, olfactory bulbs and DRG from KI mice, and pooled tissues from WT mice 944 were extracted in 1% CHAPS lysis buffer. After single-step affinity purification, 945 TAP-tagged NaV1.7 was detected using Western blotting with anti-HAT 946 antibody. 947
D
The interaction between TAP-tagged NaV1.7 and identified NaV1.7 protein-948 protein interactors including Scn3b, Syt2, Crmp2, Gprin1, Lat1 and Tmed10 949 were validated using a co-immunoprecipitation in vitro system. The expression 950 vectors containing cDNA of validated genes were cloned and transfected into a 951 HEK293 cell line stably expressing TAP-tagged NaV1.7. After transfection, 952 TAP-tagged NaV1.7 complexes were immunoprecipitated with anti-FLAG 953 antibody and the selected candidates were detected with their specific antibody 954 using Western blotting. The results showed the expected sizes of Scn3b (32 955 kDa), Syt2 (44 kDa), Crmp2 (70 kDa), Gprin1 (two isoforms: 80 kDa and 956 110kDa), Lat1 (57 kDa) and Tmed10 (21 kDa). 957
E
Tissue expression pattern of TAP-tagged NaV1.7. The proteins were extracted 958 from different tissues in both KI and WT littermate control mice and anti-FLAG 959 used to detect TAP-tagged NaV1.7 using western blotting. 960 Compared with NaV1.7 basal currents (n = 10), LCM incubation had no 971 significant effect on sodium channel density (n = 12, p = 0.402). 972 C IV plot of NaV1.7 in HEK293 cells in the presence and absence of Crmp2 973 transfection. Compared to NaV1.7 basal currents, Crmp2 transfection caused a 974 significant increase in NaV1.7 current density (n = 16, p = 0.0041). 975 D IV plot showing current density of NaV1.7 following transfection of Crmp2 and 976 incubation with 100 µM LCM. Incubation with LCM reversed the Crmp2-977 mediated current increase (n = 10, p = 0.0442). Data were analysed using one-978 way ANOVA with Tukey's post hoc test. Step 1: Flag Beads Capture
Step 2: TEV Protease Cleavage
Step 3: Ni 2+ Beads Capture
Step MGI approved gene symbols and protein names, and UniProt accession numbers are shown. Average of spectral counts from TAP-tagged Nav1.7 knock-in mice (KI) and littermate wild-type control mice (WT) and the ratios from KI group and WT group are displayed.
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